58 5.4: References
Unit 5 works cited:
- Betts, Brian C., et al. “Targeting Aurora Kinase A and JAK2 Prevents GVHD While Maintaining Treg and Antitumor CTL Function.” Science Translational Medicine, vol. 9, no. 372, American Association for the Advancement of Science, Jan. 2017. stm.sciencemag.org, doi:10.1126/scitranslmed.aai8269.
- Buchbinder, Elizabeth I., and Anupam Desai. “CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.” American Journal of Clinical Oncology, vol. 39, no. 1, Feb. 2016, pp. 98–106. PubMed, doi:10.1097/COC.0000000000000239.
- Hellmann, Matthew D., et al. “Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.” New England Journal of Medicine, vol. 378, no. 22, Massachusetts Medical Society, May 2018, pp. 2093–104. Taylor and Francis+NEJM, doi:10.1056/NEJMoa1801946.
- Li, Xiaolei, et al. “Lessons Learned from the Blockade of Immune Checkpoints in Cancer Immunotherapy.” Journal of Hematology & Oncology, vol. 11, Feb. 2018. PubMed Central, doi:10.1186/s13045-018-0578-4.
- MacDonald, Kelli P. A., et al. “Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.” Biology of Blood and Marrow Transplantation, vol. 24, no. 1, Jan. 2018, pp. 19–26. ScienceDirect, doi:10.1016/j.bbmt.2017.10.006.
- Robert, Caroline. “A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy.” Nature Communications, vol. 11, no. 1, 1, Nature Publishing Group, July 2020, p. 3801. www.nature.com, doi:10.1038/s41467-020-17670-y.
- Rotte, Anand. “Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer.” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, June 2019, p. 255. BioMed Central, doi:10.1186/s13046-019-1259-z.
- Schroeder, Mark A., and John F. DiPersio. “Mouse Models of Graft-versus-Host Disease: Advances and Limitations.” Disease Models & Mechanisms, vol. 4, no. 3, May 2011, pp. 318–33. PubMed Central, doi:10.1242/dmm.006668.
- Song, Mengjia, et al. “Future of Anti-PD-1/PD-L1 Applications: Combinations with Other Therapeutic Regimens.” Chinese Journal of Cancer Research, vol. 30, no. 2, Apr. 2018, pp. 157–72. PubMed Central, doi:10.21147/j.issn.1000-9604.2018.02.01.
- Zhang, Jun, et al. “Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.” Frontiers in Oncology, vol. 8, Sept. 2018. ResearchGate, doi:10.3389/fonc.2018.00351.